Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
HoloMonitor user Spotlight: Tianyan Wang
Tianyan talks about how digital holographic cytometry (DHC) and HoloMonitor data have been key in his Ph.D. thesis: Utility of Novel Drug Targets for Treatment of Metastatic Cancer.
Webinars in Chinese! – Everything you need to know about HoloMonitor
To help our customers who speak different languages, PHI and our local partner in China, Bio-Sun, held two webinars in Chinese to explain everything you need to know about HoloMonitor.
HoloMonitor User Spotlight: Francesco Pasqualini
Francesco Pasqualini, Associate Professor at University Pavia, tells how he applies HoloMonitor to see how ECM affects cells over a long time.
Year-end Report 2021/22
Sales more than doubled in 2021/22, compared to previous financial year.
Synthetic antibody patent awarded to PHI by Japan
PHI announces today that the Company has been granted a patent concerning synthetic antibodies in Japan.
HoloMonitor user spotlight: Robert Judson-Torres
To be a mole or to be a melanoma? Dr. Robert Judson-Torres, Assistant Professor at Huntsman Cancer Institute, University of Utah, speaks about how HoloMonitor data has been key in his recent work.
HoloMonitor user spotlight: Frida Berlin
Frida Berlin, Ph.D. student at Lund University talks about the effect of mast cell mediators on cell behavior in respiratory disease — and the role of HoloMonitor in her research.
Keep your Flow!
This webinar covers how to set up microfluidic assays to gain the most information from a single experiment.
PHI Enters Biomanufacturing Partnership with Wake Forest Institute for Regenerative Medicine
PHI and Wake Forest Institute for Regenerative Medicine recently signed a letter of intent outlining a biomanufacturing initiative to make indispensable imaging techniques available for regenerative medicine and large-scale production of cell therapies and organs.
PHI Signs Subscription Commitments with Board Members, CEO and Owners
Subscription commitments corresponding to approximately 4 % of the initial rights issue (2.9 million SEK) have been signed with members of the company’s board, the company’s CEO and with owners.